CA1093999A - Antibiotic bl580.delta. from streptomyces hygrosicopieus - Google Patents

Antibiotic bl580.delta. from streptomyces hygrosicopieus

Info

Publication number
CA1093999A
CA1093999A CA279,775A CA279775A CA1093999A CA 1093999 A CA1093999 A CA 1093999A CA 279775 A CA279775 A CA 279775A CA 1093999 A CA1093999 A CA 1093999A
Authority
CA
Canada
Prior art keywords
antibiotic
column
delta
ethyl acetate
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA279,775A
Other languages
French (fr)
Inventor
John H.E.J. Martin
Martin R. Hertz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/756,659 external-priority patent/US4138481A/en
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of CA1093999A publication Critical patent/CA1093999A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE

This disclosure describes a new antibiotic desig-nated BL580.DELTA. produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces hygroscopicus and mutants thereof. This new antibiotic is an active anticoccidial agent.

Description

26,293 10~399~

This invention relates to a new antibiotic designated BL580~, to its production by fermentation, to methods for its recovery and concentration from crude solutions and to processes for its purification. The ~-present invention includes within its scope the antibi-otic BL580~ in dilute form, as a crude concentrate and in its pure crystalline form. The effects of this new an~ibiotic as an anticoccidial agent together with its chemical and physical properties, differentiate it from previously described antibiotics.
Antibiotic B1580~ may be represented by the following structural formula which is in accordance with accepted convention in that an a-substituent is behind the plane of the paper and is represented by a ---- bond whereas a ~-substituent is in front of the plane of the paper and is represented by a _ bond.
2 ~r ~` ` 10S~999 S S~

~o , ~
~ \o ~o o~

o o~
\~

~~

1(~5 3'39~

According to the present invention there is provided a process for the preparation of antibiotic BL580~ of the formula:

Cll~O. CH3 ~ 3 :

~0 Cg,~ ' and the pharmacologically acceptable cationic salts thereof, which comprises cultivating Streptomyces hygroscopicus NRRL 8180 or mutants thereof in an aqueous nutrient medium containing assimilable sources of carbohydrate, nitrogen, and inorganic salts under submerged aerobic conditions until substantial antibiotic activity is imparted to said medium, and then reeovering antibiotic BL580~therefrom.

The novel antibiotic of the present invention is an organic carboxylic acid and thus is capable of forming salts with non-toxic, pharmaceutically acceptable cations. Thus, salts formed by admixture of the antibiotic free acid with stoichiometric amounts of cations, suitably in a neutral solvent, may be formed with cations such as the sodium ion, potassium ion, calcium ion, magnesium ion, and ammonium ion as well as the organic amine cations such as the tri ~lower alkyl) amine cations (e.g. triethylamine, triethanolamine), procaine, and the li~e. The cationic salts of antibiotic BL580~ are, in general, crystalline solids, relatively insoluble in water, and soluble in most common organic solvents such as methanol, ethyl acetate, acetone, chloroform, heptane, ether, and benzene.

The new antibiotic which has been designated BL580~ is formed during the cultivation under controlled conditions of a new strain of aJ

9~

Streptomyces hygroscopicus which also produces the known anti-biotics BL580~ and BL580~ (see United States Patent No. 3,812,249).
This new strain is a mutant derived by treatment of S. hygrosco-picus NRRL 5647 with N-methyl-N'-nitro-N"-nitrosoguanidine. A
~iable culture of the new microorganism has been deposited with the Culture Collection Laboratory, Northern Utilization Research and Development Division, United States Department of Agriculture, Peoria, Illinois, and has been added to its permanent collection.

It is freely available to the public from this depository under its accession number NRRL 8180.

The cultural, physiological and morphological - 4a -.-.5 : ., .
: ~ . :

1~3999 1 features of NRRL 8180 are substantially the same as those of NRRL 5647 as determined by Dr. H.D. Tresner, Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York. The general description of the microorganism, based on diagnostic characteristics ob-served, is the same as that for NRRL 5647 published in United States Patent No. 3,812,249, but is reproduced below for convenience.
Observations were made of the cultural, phys-iological and morphological features of NRRL 8180 in accordance with the methods detailed by Shirling and Gottlieb, Internat. Journ. of Syst. Bacteriol., 16, 313--340 (1966). The underscored descriptive colors and color chip designations are taken from Jacobson, et al., Color Harmony Manual, 3rd Edition (1948), Container Corp.
of America, Chicago, Illinois. Descriptive details are recorded in Tables I through IV below.
Amount of Growth Good on yeast extract, Kuster's oatflake, tomato paste-oatmeal and potato-dextrose agars; moderate on aspargine-dextrose, Hickey and Tresner's, inorganic salts-starch and Bennett's agars; light on Czapek's so-lution agar.
Aerial Mycelium Whitish to yellowish, becoming grayish in sporula-tion zone~ ranging from Fawn (4 ig) to Beaver (4 li) to A~hes (5 fe). Sporulation zones becoming black and hygroscopic in older cultures.
Soluble Pigments None on most media; yellowish on yeast extract, : - .;., ~ . ~
. ~ , 1~39~

1 Bennett's and potato-dextrose agars and only in light amounts.
Reverse Color Generally in yellowish shades on most media.
5 Miscellaneou~ Physiological Reactions Nitrates reduced to nitrites; complete liquefaction of gelatin; no formation of melanoid pigments on peptone--iron agar; complete peptonization of purple milk in 7 days; tolerance of NaCl in growth medium > 7 percent but ~ 10 percent. Carbon source utilization according to the method of ~ridham and Gottlieb, J. Bacteriol., _, 107-114 (1948) as follows: Good utilization of adon-itol, d-galactose, d-fructose, d-raffinose, salicin, d-xylose and dextrose; poor or no utilization of d-melezi-tose, d-melibiose, l-arabinose, i-inositol, lactose, d-mannitol, l-rhamnose, sucrose and d-trehalose.
Micromorpholog~
Aerial mycelium gives rise to spore-bearinc branches which terminate in tightly coiled spirals of several turns; pores are mostly isodiametric, cylindrical, phalangiform, 0.6-0.7~m x 0.7-0.8,um. Spores smooth as determined by electron microscopy; ~pore sheaths finely wrinkled.
On the basis of the general characteristics observed, microorganism NRRL 8180 is a member of a large group of streptomycetes characterized by gray spores, spiral spore chains, smooth-walled spores and lack of melanin pigments. The hygroscopic nature of the culture along with its entire composite of morphological and physiological characteristics makes it a representative 39~9 strain of Streptomyces hygroscopicuc as defined by H.
D. Tresner and E. J. Backus, "A Broadened Concept of the Characteristics of Streptomyces hygroscopicus", Appl. Microbiol., 4, 243-250 (1956) and ~. D. Tresner, 5 E. J. Backus and J. A. Hayes, "Morphological Spore Types in the Streptomyces hygroscopicus-like Complex", Appl.
Microbiol., 15, 637 639 (1967).

~0 39~

U U ~, ~U
~ . _~ O ,, ~ C _~
~ ~ Vc ~ L~ Vc U~
V Ll .C U o C U C. N O
9~ C C N C C N 11) _1 C C N
Vl o '~'~ ,a C,0~5, ~ U) o u ~ ~ 8 ~ ~ u O h O _ ~
~ U ~ _ ~ ~ _ z ~ ~o 8 v N oo ,u~l ~03 ~ C lal ~
~ .. _ .
O . ~V~ ~r ~ ~ tl C 0'~ O C C . C , U~ ~ ~.rl __ _.. _.
v . ~ . 0 ~ ~:
8 ~ V ~ I ~C I I ,~ O
E~ ~ e, .~ v ~ v ~ O ~ v u ~ ~
q.l .,1 U r~ C3 ~ 'C ~ ~ 3 ul 8 o~ e E ~ ,c u~ ~ ~ v u E ,~ v ''~ 3-ek Vi ~ 3k; ul .,.~ 1 v 1~ .3 v u ~t c ~ 1~ u ~UJ ~ OD.
.~ ~ ~ ~ ~ e ~r ON ~0 e ~ ON e -~ u' vu 16 ~ o ,~ O c ~ o~e ~ ~
~a u u vl r~ o :~ ~ c r~ o ~ .~ e ~ o c ~ .
_ ~ ~o ~ ~ v o 5 u ~ o ~ ~ ~
I~J V'3 V V
V 3 C ~3 O - . ~:
:' _ ,0 .~ .. ___ ~1 ~ V~U ~ X .
C .~ .~ ~X O C

h U~ ),~ ~1 C ,a Id ~ ~ Ul ~ U~ ~ ~ ~

10~ 9~9 ~ ~ o ~ j:

xoo ~L'8 ~uo~ ~8 o 8 ~ ~ ~i e A I l 1~ 3 ~ 1~ ¦
_ ~1 8 :~ 3c ~c u o~ ~.~
v ! be St~ Zb-~ cs ~ ~a o~ 2~ 0 ~ ~ o ~ ~c` o~ ~ 5 c-V~

~ ~ o ~ ~ l ~
~ c ~ ~ ~ c~i ~ ~ i Y

- -- 9 - :

1~399~
U U
o~ Q~,, 0 h ~) .
~ r~C S~ ~
td ~1 .C C N
~ ~t: ,0 1~ ~
~ O ~ O
oE~

~ i ' 00 ~ .C`

~ ~ i) 3 ~ ~ : ~ , ~ .
.~ ~ O I
~ O ,CSI~rlO

H~ . ~ ~ ~
~1 u~ ~ 1 3 C ~r 0 nO ~ O.~ .
~a t~ ~ 1~ E~ C
E~ 0 ~ ul :~ O ~ O
O Ei~1 U ;~ N (O
~0 la ~ a) ,q ~ c~ , .~ '~ ~ ~0 'J~ EOi~
~ a~ ~ .,~ ~
3^
~ . ,1~ o.
S ~ P
~ _ :~ ~30 ~
1~
~1 ~ ,~, .~ .~ X
~ ~0 .: .~ ',; .. , ' . . . ` ': , . ~ :

,........................ 1~3g~9 ' ~2 aJ ~
~, ,, ~ ~,, .
ut ~n Q.
~ ~o - a) ~
~ s U~ s , o ~ o P. o o X X
,, .,1 3 . ~ U~ t` CO
~ ~ 00 `~
O ~
~1 ~ E3,0~E3, . ..
U~ ~ ~ ~ O , ,.
S ~1 ' H Cl ~rl-rl H U~~ E ~
~ o U~ ' ~ ~ ~ ~ ' o o_ ~ O Q ~ ~ ' .
E~ n U~-rl U Q~ . .
~ ~ ' U~~ U~ ~ ' a~ ~ ui O ~ U .~ ' ::~ t~
O ~ ~ ~ A ~I r O ,1 U~ .C ~I ~
.c _l ~ a.\ c.~ o )-I
8 ~ ,, o .~
2 :~0 U ~ ~a) ~ ~ ~ q ,~ ~ 0 ~ ' O ~ _1~ ~0 ~rl rl ~ ~ O-rl ' X~ O r~ Q
a) ~
In ~ a . . ~ . .. _ ~ .

rl ~
~ ~-~ .

~ 11 ~

- .
', . ' ' ' ' . ' ' ' ' .

o rol o u~ ,~
oo ~ o o ,~
~1 u ~ ~ ~ ~ ~
01~ (~1 U a~ N
~U
~:1 ~
--I V ~u ~ u ~ jr1 z ~ ~
~ ~ o Ul ~
:~ O~ , , n a.) V
u o 0 u~
~1 ~1 ~ o ~ ~ l U a~
o ,~ ~ 1 ,q U tq ),~
U~ ~ ~ ~ ~ U ~ UdP
s ~ a z a 8 : ~' 8 ~
~ . .
u) ~ . .
a) o u ~
~ o o o o o o .
o si o o ~ o ~ ~
~ ~ ~ .
H CJ v .
H U~ _ _ ~ O _~ . . ~ ~.
5~ U~ CO ~
E~ O ~ u~ O u~ U~ ' .~ ~ ~~ ~ ~ ~ .
~ ~:: ~ a /a .
~ rl a ~ a r~ o ~: ~ ~

U ~H .
O _ _ .
O ~ ~

Ul ~ ~Z.
.C h S~ ~ _ u~
O :~
~rl ~ ~ S U ~
~:1 ~ ~ O .Y la ~ .
.,~
_1 ~ ~ X
U U
~ ~
Ul ~ ~ ~ O
~1 ~
X' t~ ~1 ~ h /~ ' ) 1 O O ~ P~ P1 ~`' : .. , . .. :
..... : :.

3g~9 Table IV
Carbon Source Utilization Pattern of Streptomyces hygroscopicus NRRL 8180 Incubation: 10 Days Temperature: 28C
Carbon Source Utilization*

Adonitol 3 :
l-Arabinose 0 Dextran 3 d-Fructose 3 i-Ino~itol 0 Lacto~e 0 d-Mannitol 0 d-Melezitose d-Melibio~e d-Raffinose 3 l-Rhamnose O
Salicin 3 Sucrose 0 d-Trehalo~e 0 d-Xylose 3 Dextrose 3 Negative Control 0 ~3 - Good utilization 2 ~ Pair utilization 1 - Poor utilization 0 - ~o utilization .
,. . . .

1 It i5 to be understood that for the production of BL580Q, the present inventicn is not limited to this particular microorganism or to microorganisms fully ans-wering the growth and microscopic characteristics of 5 NRRL 8180. In fact, it is desired and intended to in-clude the use of mutants produced from NRRL 8180 by var-iou mean~, such as X-radiation, ultraviolet radlation, nitrogen mustard, phage exposure and the like.
Antibiotic ~L580~ is highly effective in con-trolling coccidial infections in a warm-blooded animal host. Furthermore, antibiotic BL580~ is markedly less toxic than antibiotic BL580~ (whose structure is set forth in Netherlands Patent No. 7,402,938). The activ-ity of antibiotic BL580~ as an anticoccidial agent was demonstrated by the following ln vlvo tests wherein the following poultry diet was used.
Viatamin-Amino Acid Premix 0.5~
Trace Minerals 0.1%
Sodium Chloride 0.3~
Dicalcium Phosphate 1.2%
Ground Limestone 0.5%
Stabilized Fat 4.0%
Dehydrated Alfalfa (17% protein) 2.0%
Corn Gluten Meal (41% protein) 5.0%
Menhaden Fish Meal (60~ protein) 5.0~
Soybean Oil Meal (44% protein) 30.0%
Ground Yellor Corn, fine to 100~
The vitamin-amino acid premix in the above poultry diet was prepared from the following formulation.
The expressions of quantity relate to units per kilogram 10~3999 1 of the poultry diet.
Butylated Hydroxy Toluene125 mg.
dl-Methionine 500 mg.
Vitamin A 3300 I.U.
Vitamin D3 1100 I.C.U.
Riboflavin 4.4 mg.
Vitamin E 2.2 I.U.
Niacin 27.5 mg.
Pantothenic Acid 8.8 mg.
Choline Chloride 500 mg.
Folic Acid 1.43 mg -Menadione Sodium Bisulfate 1.1 mg.
Vitamin B12 11 mcg.
Ground Yellow Corn, fine to5 gm.
Mixed Coccidia Infections of Eimeria tenella _ and Eimeria acervulina A mixed inoculum of 5000 sporulated oocysts of Eimeria acervulina and a sufficient number of oocysts of Bimeria tenella to produce 85% to 100% mortality in un-treated controls was given to groups of seven-day-old chicks, by direct in~culation into the crops of all chicks. The chicks were given free access to the poul-try diet and water during the entire test period. Two days after inoculation, medicated feed, compofied of the poultry diet and several levels of BL580~, was presented to the various groups of chicks in the test. Ten days after incoulation the tests were terminated. The chicks were weighed, necropsied and their intestinal tracts examined for lesions. The results of this test appear in Table V. Theee results show that 100~ ~urvival of $()5~3'3~9 l infected chicks was obtained when 125 ppm or 250 ppm of BL580~ was administered to infected chicks in their diet. These results also show a significatnt suppres-sion of lesions due to Eimeria tenella and Eimeria acer-vulina when 30 ppm or 60 ppm of BL580~ is administeredto infected chicks in their diet.

; ~

~3999 ¦ o ~ I o o o r I

3 0a¦ .

~ O O O ~D O
~a 1 ~r :~ _ ~I
a) ~ ~ ~o '~ r~ o o _i o E~ ~ ~ _l o o a~ ~D
P~ U~ ~ .
. .._____~
.
o~
a~ u~ o u~
~ ~a ~
m _ _ , ,o~
o .~
~ ~ O O U~ O C
~ ~ U~ ~ ~ ~
~1 ~ _1 ~ ~1 .
o~ .

10?~39~9 1 ~ixed Coccidia Infection of Eimeria tenella, Eimeria acervulina, Eimeria necatrix, Eimeria brunetti and Eimeria maxima A commercial vaccine (Coccivac~ D, Sterwin Lab-oratories, Opalika, Alabama) containing a mixture of at least five species of Eimeria coccidia, was administer-ed to chicks at 70 times the normal immunizing dose.
The vaccine was given to groups of ~even-day-old chicks, by direct inoculation into the crops of all chicks. The chicks were given free access to water and the above poultry diet during the entire test period. Two days - after inoculation medicated feed, composed of the poul-try diet and several levels of BL580~, was presented to the various groups of chicks in the test. Ten days after inoculation the tests were terminated and the birds were weighed, necrcpsied and their intestinal tracts examined for lesions. The results of this test appear in Table VI. These results show that 100% sur-vival of infected chicks is obtained when 120 ppm of BL580~ is administered to infected chicks in their diet.
This level also shows a significant suppression of les-ions due to Eimeria tenella, Eimera acervulina, Eimeria necatrix, Eimeria brunetti and Eimeria maxima.

lV~ 39S~

~1 ~ -Xl ~ ~o co .o ~. 1 o a~ o ~ 41 _1 ~
~1 a~) Xl ~-P~ ~ ~- o o o ~o '3 11~ ~ ~
L~ 1~ ~ O O ~ 1~.

a 0 o al ~1 ~ ~
~rl o o o~:
U~
_ .
o ~ .
~ ~ U~

Z ~ :
4~ .
OQ.
o ~
~ o o o o h 1: ~ ~ ~
~ _1 ~:

1 Fermentation Process , Cultivation of the microorganism Streptomyces hygroscopicus NRRL 8180 may be carried out in a wide variety of liquid culture media. Media which are useful for the production of antibiotic BL580~ include an assim-ilable source of carbon such as starch, sugar, molasses, glycerol, etc.; an assimilable source of nitrogen such as protein, pro~ein hydrolysate, polypeptides, amino acids, corn steep liquor, etc.; and inorganic anions and cations such as potassium, sodium, calcium, sulfate, phosphate, chloride, etc. Trace elements such as born, molybdenum, copper, etc. are supplied as impurities of other constituents of the media. Aeration in tanks and bottles is provided by forcing sterile air through or onto the surface of the fermenting medium. Further agi-tation in tanks i8 provided by a mechanical impeller.
An antifoaming agent such as one percent octadecanol in lard oil may ~e added as needed.
Inoculum Pre~aration Shaker flask inoculum of Streptomyces hygro-scopicus NRRL 8180 is prepared by inoculating 100 ml.
portions of sterile liquid in 500 ml. flasks with scrap-ings or washings of spores from an agar slant of the culture. The following medium is ordinarily used:
Soy flour 1.0%
Glucose 2.0%
Corn steep liquor 0.5%
CaCO3 0.3%
Water qs 100%

The flasks are incubated at a temperature from :, ~

10~3999 1 25C. to 29C., preferably 28C. and agitated vigorou~ly on a rotary shaker for 48 to 96 hours.
Two 100 ml. portion~ of this inoculum are used to inoculate 12 liter~ of the same sterile medium in a 20 liter bottle. This inoculum i8 incubated with agita-tion and aeration of sterile air for 36 to 64 hours at 25C. to 29C., preferably 28C.
This inoculum is used to inoculate 30~ liters of the same sterile medium in a tank fermentor. This inoculum is incubated with agitation and aeration of ~terile air for 36 to 64 hours at 25C. to 29C., pref-erably 28C.
This inoculum is used to inoculate a 40~0 liter fermentation tank containing 3000 liters of a sterile medium such as the following:
Corn steep liquor 0.5%
Soy flour 1.0%
Corn starch 4.0 CaC~3 0.1~
Water qs 100%
This medium i5 fermented for 100 to 200 hours at a temperature of 27C. to 32C. with agitation by an impeller and aeration at a rate of 0.4-0.8 liter~ of air per liter of medium per minute. Normally a defoamer such as Hoda~ FD82 i~ added at a ratio of about 1.3 gal./1000 gal. of medium.
Purification Procedure , .
After the fermentatioTI i8 completed, the fer-mented ma~h containing antibiotic ~L580~ i~ combined with about one-half it~ volume of ethyl acetate and stirred Registered Trademark B

~0~3999 1 for 2-3 hours. An approximate 8% portiOn of diatomace-OU5 earth is added and the mixture is filtered through a plate and frame filter pres3. The cake is washed on the press with ethyl acetate. The ethyl acetate ex-tract~ are collected and concentrated in a still toa syrup.
The above syrup is stirred with twice its vol-ume of heptane and stored at 4C. overnight. The super-natant is recovered by decantation and concentrated to a gummy residue.
The gummy concentrate is treated with 10 liters of methanol and chilled with the aid of dry ice for sev-eral hours. The mixture is filtered through sintered glass with diatomaceous earth precoat and washed with cold methanol. The methanol solution is concentrated to dryness ln vacuo.
A chromatographic column is prepared with ac-, tivated carbon at a ratio of about one liter of carbon per 50 g. of charge. The dried residue is dissolved in methylene chloride at a ratio of 40 g./liter and chargedon the column. The methylene chloride eluate is collec-' ted as one cut and concentrated to dryness. The residue is mixed with methanol and stored in a chill room with dry ice to reduce the temperature to -10C. for 15 min-, 25 utes. After 15 minute9 the solidified oil is filtered off and the methanol soluble material is concentrated to I dryness in vacuo giving an oil.
:. _ Thi~ oil is dissolved in a minimum aount of methylene chloride, combined with ~ilica gel, concentrat-ed to dryness and charged on a dry silica gel column.

:~

- 2~ -.. . .

, ~

1 The column i8 developed with 10% ethyl acetate in ben-zene followed by 20% ethyl acetate in benzene. The column is then allowed to drain. The column is meas-ured into 10 equal parts (including the charge). Core samples are removed at Rf 0.05, 0.15, 0.25, 0.35 ...etc., for the length of the entire column and eluted with an appropriate volumn of ethyl acetate:methylene chloride:-methanol (2:2:1). At places where the antibiotic over-lap~, core samp1ing is done at every 1/8 of an Rf unit.
The antibiotic is located by thin layer chromatography of the core elutates on commercially available thin lay-er plates (Silplate-22*distributed by Brinkmann Instru-ment Co., Westbury, New York 11590). The respective zones were detected by charring in the presence of sul-furic acid.
The section of the column comprising Rf 0.11to 0.35 is excised from the column and slurried in ethyl acetate:methylene chloride:methanol (2:2:1 by volume~.
This mixture is filtered, washed with additional solvent mixture and concentrated ln vacuo to dryness. The resi-due is dissolved in t-butanol, filtered and freeze dried to give a ~luffy solid.
A two-phase system is prepared by mixing n-heptane:methanol:ethyl acetate:water (3000:1500:75:37 by volume). Celato~ (Eagle-Picher Industries, Cincinnati, Ohio), a brand of dia~omaceous earth, is mixed with the lower phase of this system at a ratio of about 800 g./600 ml. of lower phase and packed in increments into a (7.5 cm. in diameter) column. The charge is applied as a mixture of diatomaceous earth, lower phase and lyophil-Registered Trademark 3~3~9 1 lized product (40 g.:30 ml.:13.8 g.). The charged col-umn is d~veloped with upper phase and fractions of 25 ml.
are collected. The activity is detected by thin layer chromatography on selected fractions using a gelplate, chloroform:ethyl acetate (1:1) as developer and charring for detection. Fractions 90-150 are combined and con-centrated giving antibiotic BL580~/
The invention will be described in greater de-til in conjunction with the following specific examples.
Example 1 Inoculum Preparation A typical medium used to grow the primary in-oculum is prepared according to the following formula:
Soy flour 1.0 g.
15 Glucose 2.0 g.
Corn ~teep liquor 0.5 g.
CaCO3 0.3 g.
Water to 100 ml.
The washed or scraped spores from an agar alant of Stre~_ myces hygroscopicus NRRL 8180 are used to inoculate two 500 ml. flasks each containing 100 ml.
of the above medium which has been sterilized. The flasks are placed on a rotary shaker and agitated vig-orously for 72 hours at 28C.
The resulting flask inoculum is transferred to a 5 gallon glass bottle containing 12 liters of the same sterile medium. This secondary inoculum is aerated with sterile air while growth is carried out for 48 hours at 28C.
~ 30 The resulting secondary inoculum is transferred ; - 24 -:

i()~39~

1 to a 100 gallon tank containing 300 liters of the same sterile medium. This tertiary in~culum is aerated with sterile air at the rate of one liter of air/liter of med-ium/minute and agitated by an impeller operating at 173 rpm. Growth is continued for 48 hours at 28C. The pH
at this time is 6.9 to 7Ø
Example 2 Fermentation A fermentation medium i8 prepared according to the following formula:
Corn steep liquor o.s g.
Soy flour 1.0 g.
Corn starch 4.0 g.
CaCO3 0.1 g.
Water to 100 ml.
A 3000 liter batch of fermentation medium of the above formulation in a 4000 liter tank is ~terilized at 120C. for 60 m~nutes. The pH of the medium after sterilization is 6.4 to 6.5. This medium is inoculated with 300 liters of tertiary inoculum prepared as describ-ed in Example 1. The fermentation is carried out at 28--30C., using 4.0 liters of Hodag FD82 as a defoaming agent. Aeration is supplied at the rate of 0.6 liter of sterile air per liter of mash per minute. The mash is agitated by an impeller driven at 150 rpm. At the end of 138.5 hours of fermentation time the mash i9 harvested.
Example 3 Iqolation and Purification A 2550 liter portion of fermented mash prepared as described in Example 2, having a pH of 7.4 i~ combined ':

-, .~, 1~3~9 1 with 1275 liters of ethyl acetate and stirred for 2.5 hour~. An 8~ (by weight) portion of diatomaceou~ earth i8 added. The mixture is filtered in several portions, with stirring, through a pair of frame presses. The aqueous-ethyl acetate filtrates are pooled providing 3250 liters which is allowed to separate, providing 1000 liters of ethyl acetate extract. After each portion of mash-ethyl acetate-diatomaceous earth is filtered through a press, the pad is washed on the press with ethyl ace-tate. The ethyl acetate wa3hings are combined and sep-arated giving 535 liters of ethyl acetate washings. The 1000 liters of ethyl acetate extracts and 535 liters of ethyl acetate washings are combined and concentrated in a 400 gallon still to 225 liters. This 225 liters is further concentrated in a 50 gallon still to 20 liters.
This 20 liters is further concentrated in a glass still to a syrup.
The syrup iB stored at 4C. for 48 hours and then stirred with twice its volume of heptane. The mix-ture is allowed to stand at 4c. overnight. The super-natant i8 recovered by decantation and concentrated to a gummy residue.
A 10 liter portion of methanol is added to the gummy residue and the mixture is chilled with the aid of dry ice for several hours. The mixture is filtered through sintered glass containing a diatomaceous earth precoat and washed with cold methanol. The combined filtrate and washings are concentrated to dryness ln vacuo providing 1353.5 g. of residue.

-The 1353.5 g. of residue is dissolved in meth-1 ylene chloride at a rate of 40 g./liter. A chromato-graphic column is prepared by packing with 27.07 liters of 20 x 40 mesh granular carbon. The residue in meth-ylene chl~ride is passed through this column at a flow rate of 375-400 ml. per minute. The methylene chloride eluate is collected as one cut and concentrated to dry-ness giving 1053 g. of residue. The residue is thor-ou~hly mixed with 8-9 liters of methanol. The mixture i~ reduced to -10C. in a chill room with the aid of dry ice and maintained at -10C. for 15 minutes. Any solid-ified oil is removed by filtration and the methanol fil-trate is concentrated to dryness in vacuo giving 781.4 g. as an oil.
A dry pack chromatographic column is prepared by packing 4 kg. of silica gel onto a 12" circumference plastic column. A 200 g. portion of the above oil is dissolved in a minimal amount of methylene chloride. A
;I 300 g. portion of silica gel is added and mixed thoroughly and the mixture is then concentrated in vacuo to dryness.
The dried mixture is charged on the column and some sea sand is placed on the top of the column to prevent bed disturbance during elution. The plastic column is placed in a glass shell to give it support. The column is eluted with 12 liters of 10~ ethyl acetate in benzene.
The column is allowed to run dry and then eluted with 7.6 liter~ of 20% ethyl acetate in benzene. Cuts are collect-ed and the column is allowed to run dry. The column is then purged with nitrogen. Antibiotic activity is de-termined by assaying the cuts vs. Streptococcus pyogenes NY5. The column is measued into 10 equal parts (includ-. .

., . .:

~0~3~9~

1 ing the charge). Core samples are removed at Rf 0.05, 0.15, 0.25, 0.35..... etc., for the length of the entire column. At places where the antibiotic bands overlapped, core sampling is done at every 1/8 of an Rf unit. Each core,sample is eluted with 10 ml. of ethyl acetate:meth-ylene chloride:methanol (2:2:1) and examined by thin layer chromatography using the system ethyl acetate:-chloroform (1:1) spotting 30 of sample and charring with sulfuric acid. The section of column Rf 0.11 to Rf 0.35 is removed and slurried in ethyl acetate:methylene chloride:methanol (2:2:1). The mixture is filtered and washed with the same solvent mixture and concentrated to dryness ln vacuo. The residue is dissolved in t--butanol, filtered and lyophilized giving 26.7 g.
A two-phase system i5 prepared by mixing n-heptane:methanol:ethyl acetate:water [3000:1500:75:37 ; (by volume)]. An 800 g. portion of acid washed diato-maceous earth is mixed with 600 ml. of the lower phase of this solvent sy~tem and packed in increments into a 7.5 cubic inch gla~s column. The charge, comprising 40 g. of diatomaceous earth, 30 ml. of lower phase solvent and 13.8 g. of the above lyophilized material, is applied as a mixture. The charged column is developed with the upper phase of the solvent system and 25 ml. fractions are collected. The desired compound is located by assaving fraction samples as above with thin layer chromatography. Fractions 90-150 are combined and lyophilized providing 2.75 g. of the product BL580~ pri-marily as the sodium salt.

1 Example _ Preparation and Isolation of BL580~ as the Free Acid The partial sodium salt of BL580~ is prepared and isolated as described in Exampels 1-3. A two-phase system is prepared by mixing heptane, methanol, ethyl acetate, water (3000:1500:80:40 by volume). A glass column is packed with a mixture of 800 g. of diatomace-ous earth and 600 ml. of the lower phase of the above system. The charge is applied as a mixture of 28 g. of diatomaceous earth, 21 ml. of lower pha~e and 10.9 g.
of the BL580Q partial sodium salt. The column is de-veloped with upper phase. Fractions of 90 ml. volume are collected. Selected fractions are chromatographed on Silplate~ F-22 using ethyl acetate:chloroform as de-veloper and charring for detection in order to locatethe BL580~. Fractions 29-39, containing the BL580~
are combined and the solvent is removed. The resulting solid i8 redissolved in t-butanol and lyophilized giv-ing 4.79 g-An 800 mg. portion of this lyophilized mater-ial is stirred in 300 ml. of a two-phase system composed of water:ether:petroleum ether (2:1:1). The pH is ad-justed to 2.5 using lN HC1 while stirring. The organic phase is separated and washed three times with an equal volume of water. The solvent extract is concentrated in vacuo to a residue. The residue is dissolved in t--butanol and then lyophilized giving 657 mg. of BL580 as the free acid.
~he free acid of BL580~ has microanalytical data as follows: C, 61.10; H, 8.9; ash, 0; and a spe-;. . :. : .......... .

10~3999 l cific rotation l~]25 = +21 + 1 (C=0.9 in methanol).
The free acid of BL580~ exhibited character-istic absorption in the infrared region of the spectrum at the following wavelengths: 2.95; 5.88; 8.35; 8.60;
9.00; 9.12; 9.43; 9.62; 10.05; and 10.47~.
A standard infrared absorption spectrum of the free acid of BL580~ prepared in a KBr pellet is shown in Figure 4 of the accompanying drawings.
A standard proton magnetic resonance spectrum of the free acid of BL580~ is shown in Figure 5 of the accompanying drawings.
A standard C nuclear magnetic resonance spectrum of the free acid of BL580~ is shown in Figure 6-of the accompanying drawings.
; 15 Example 5 Preparation of the Sodium Salt of BL580~
BL580~ free acid (1 g.) is dissolved in 300 ml.
of ether~petroleum ether ~1:1). This solution is added to 200 ml. of water to give a two-phase system. The pH
is adjusted to 10.0 by the addition of 0.1N NaOH while stirring, after which the organic phaee is separated and concentrated in vacuo to a residue~ The residue is dis-solved in 10 ml. of ether and 20 ml. of petroleum ether (30-70C.) is added. The resulting solution is seeded with a crystal of BL580~ sodium salt and allowed to evap-orate slowly at 4C. until a crystalline solid forms.
The crystals are collected on a filter, washed with cold petroleum ether and air dried to yield 323 mg. of the sodium salt of BL580~.
; 30 This sodium salt of antibiotic BL580~ has a :.

. . .

1~3999 1 melting point of 157-161C.; C, 60.99; H, 8.47; Na, 1.95: [a]25 = +6 + 1 (C=1.153 in methanol). The sod-ium salt of BL580Q exhibited characteristic absorption in the infrared region of the spectrum at the following wavelengths: 6.27, 7.28, 9.0, 9.13, 9.23, 9.48 and 10.60,u.
A standard infrared absorption spectrum of the sodium salt of BL580~ prepared in a KBr pellet i8 shown in Figure 1 of the accompanying drawings.
A standard 13C nuclear magnetic resonance spectrum of the sodium salt of BL580~ is shown in Figure 2 of the accompanying drawings.
A standard proton magnetic resonance spectrum of the sodium salt of BL580~ is shown in Figure 3 of the accompanying drawings.
Example 6 Preparation and Isolation of the ~-Bromophenacyl Ester of BL580Q _ _ The partial sodium salt of BL580~ is prepared and isolated as described in Examples 1-3. A one gram portion of this BL580~ sodium salt, 834 mg. of p-bromo-phenacyl bromide, 600 mg. of lithium carbonate and 20 ml.
o dry dimethylformamide are placed in a flask and allow-ed to react at 37C. for 16 hours. Four volumes of chloroform are added and the resulting suspension is filtered. The filtrate is concentrated in vacuo to remove the ~olvent giving a syrupy re~idue. A diatomaceous earth partition column is prepared using a system com-posed of heptane:ethyl acetate:methanol:water (2000:25:-1000:17). A 120 g. portion of diatomaceous earth and 90 ..

`` 1(3S~3999 1 ml, of lower phase are used for the column. The syr-upy residue, 12 g. of diatomaceous earth and 9 ml. of lower phase are applied to the top of the column. The column is developed with upper phase. Fractions of 10 ml. each are collected. The activity in the fractions is located by thin layer chromatography. Fractions 22-41 are combined and concentrated in vacuo to a residue. The residue is dissolved in 50 ml. of methanol and filtered.
Thç filtrate is warmed on a steam bath, 10 ml. of water is added and the mixture is allowed to cool slowly to 4C.
The resulting crystals are collected giving 566 mg. of ., BL580Q as the p-bromophenacyl ester.
The ~-bromophenacyl ester of BL580~ has micro-analytical data as follows: C, 58.80; H, 7.~0; Br, 8.64;
a specific rotation [~]25 = +63 + 2 (CHC13 at 0.51%).
The ~-bromophenacyl ester of BL580~ exhibited characteristic absorption in the infrared region of the spectrum at the following wavelengths: 2.95; 5.88; 6.30;
8.20; 8.45; 8.60; 9.00; 9.15 (braod); 9.37 (broad); 9.62;
10.06; and 10.37.
The molecular weight of the ~-bromophenacyl ester of BL580~ monohydrate is 1114 + 0.3% as determined by X-ray diffraction.
A standard infrared absorption spectrum of the ~-bromophenacyl ester of BL580~ prepared in a KBr pellet is shown in Figure 7 of the accompanying drawings.
A standard ultraviolet absorption spectrum of the ~-bromophenacyl ester of BL580~ prepared at a concentration of 33.84 mcg./ml. in methanol is shown in Figure 8 of the accompanying drawings.

:. . .

1 A standard proton magnetic resonance spectrum of the p-bromophenacyl ester of BL580~ is shown in Fig-ure 9 ~f the accompanying drawings.

'~ :
! ~
,: ;

;J
P~ 30 ,':
,: , ,~, . . .

. , . , ~ ... ;: :

Claims (2)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for the preparation of antibiotic BL580.DELTA. of the formula:

and the pharmacologically acceptable cationic salts thereof, which comprises cultivating Streptomyces hygroscopicus NRRL
8180 or mutants thereof in an aqueous nutrient medium con-taining assimilable sources of carbohydrate, nitrogen, and inorganic salts under submerged aerobic conditions until substantial antibiotic activity is imparted to said medium, and then recovering antibiotic BL580.DELTA. therefrom.
2. The compound antibiotic BL58.DELTA. of the formula:

whenever prepared according to the process of Claim 1 or by an obvious chemical equivalent thereof.
CA279,775A 1976-06-04 1977-06-03 Antibiotic bl580.delta. from streptomyces hygrosicopieus Expired CA1093999A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70139576A 1976-06-30 1976-06-30
US05/756,659 US4138481A (en) 1976-06-30 1977-01-04 Antibiotic BL580Δ and method of use
US756,659 1977-01-04
US701,395 1985-02-14

Publications (1)

Publication Number Publication Date
CA1093999A true CA1093999A (en) 1981-01-20

Family

ID=27106775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA279,775A Expired CA1093999A (en) 1976-06-04 1977-06-03 Antibiotic bl580.delta. from streptomyces hygrosicopieus

Country Status (22)

Country Link
JP (1) JPS5356668A (en)
AR (1) AR212717A1 (en)
AT (1) AT358725B (en)
AU (1) AU514519B2 (en)
CA (1) CA1093999A (en)
CH (1) CH636642A5 (en)
DD (1) DD144561A5 (en)
DE (1) DE2728596A1 (en)
DK (1) DK282577A (en)
ES (1) ES460266A1 (en)
FR (1) FR2356667A1 (en)
GB (1) GB1560817A (en)
GR (1) GR73051B (en)
IE (1) IE45349B1 (en)
IL (1) IL52205A (en)
IT (1) IT1079709B (en)
NL (1) NL7707283A (en)
NZ (1) NZ184262A (en)
PL (1) PL105378B1 (en)
PT (1) PT66700B (en)
SE (1) SE7707552L (en)
YU (1) YU156677A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150152A (en) * 1977-10-26 1979-04-17 Pfizer Inc. Polycyclic ether antibiotic produced by a strain of streptomyces hygroscopicus
FR3078629B1 (en) 2018-03-12 2020-07-31 Adisseo France Sas SAPONIN-BASED FOOD ADDITIVE FOR THE TREATMENT OF COCCIDIOSIS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812249A (en) * 1972-11-24 1974-05-21 American Cyanamid Co Antibiotic bl580
CH579147A5 (en) * 1973-03-09 1976-08-31 Sandoz Ag Antiparasitic streptomyces hygroscopicus metabolite - i.e. septamycine, as antibacterials, antiprotozoals, anthelminthics and coccidiostats
DK133254C (en) * 1973-03-09 1976-09-13 Sandoz Ag PROCEDURE FOR THE PREPARATION OF AN ANTIBIOTIC SEPTAMYCIN OR SALTS THEREOF

Also Published As

Publication number Publication date
JPS5356668A (en) 1978-05-23
FR2356667A1 (en) 1978-01-27
IE45349B1 (en) 1982-08-11
DD144561A5 (en) 1980-10-22
AU2582377A (en) 1978-12-07
AU514519B2 (en) 1981-02-12
AT358725B (en) 1980-09-25
PT66700A (en) 1977-07-01
YU156677A (en) 1983-01-21
NL7707283A (en) 1978-01-03
PL199271A1 (en) 1978-09-11
GR73051B (en) 1984-01-26
IT1079709B (en) 1985-05-13
GB1560817A (en) 1980-02-13
IL52205A (en) 1980-05-30
CH636642A5 (en) 1983-06-15
NZ184262A (en) 1980-08-26
FR2356667B1 (en) 1981-12-31
PT66700B (en) 1978-11-20
PL105378B1 (en) 1979-10-31
IL52205A0 (en) 1977-07-31
DK282577A (en) 1977-12-31
IE45349L (en) 1977-12-30
AR212717A1 (en) 1978-09-15
SE7707552L (en) 1977-12-31
ATA463077A (en) 1980-02-15
DE2728596A1 (en) 1978-01-12
ES460266A1 (en) 1978-10-01

Similar Documents

Publication Publication Date Title
US3501568A (en) Novel antibiotic a3823 complex and process for production thereof
EP0026338A1 (en) Antibiotic C-15003 PHM, production thereof and microorganisms for its production
CA1142866A (en) Antibiotic a/16686 and process for the preparation thereof
US4407946A (en) Process for producing antibiotic X-14868A
US4559301A (en) Process for preparing macrocin derivatives
US4138481A (en) Antibiotic BL580Δ and method of use
US4252898A (en) Antibiotics A6888C and A6888X
EP0185456A2 (en) CL-1577D and CL-1577E antibiotic/antitumor compounds, their production and use
US4384043A (en) Process for producing the antibiotic nosiheptide
CA1093999A (en) Antibiotic bl580.delta. from streptomyces hygrosicopieus
GB1563432A (en) Antitumor anthracycline glycosides
US4189537A (en) Process of producing antibiotic BL580Δ with Streptomyces hygroscopicus
US4497797A (en) β-Galactosidase inhibitor GT-2558 and its derivatives
US4152424A (en) Antibiotic 1745A/X and methods for the production thereof
US3812249A (en) Antibiotic bl580
US3992264A (en) Antibiotic 1745A/X and methods for the production thereof
US4336333A (en) Process for preparing tunicamycin
US4204038A (en) Process for preparing antibiotics MA 144-M1 and MA 144-M2
US3932619A (en) Metabolite A-27106 and processes for its preparation and use
US4358584A (en) Antibiotics A6888C and A6888X
US4132779A (en) Antibiotic BL580 Zeta and use thereof as anticoccidial agent
KR960005150B1 (en) Novel pyrazinoxide compound of nf-1616-904
US3950516A (en) Process for preparing cirramycin A1
EP0058838A1 (en) Antibiotic LL BO1208 alpha and LL BO1208 beta
US4070376A (en) Antibiotic 1745A/X and methods for the production thereof

Legal Events

Date Code Title Description
MKEX Expiry